TITLE

Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men

AUTHOR(S)
Pignone, Michael; Earnshaw, Stephanie; McDade, Cheryl; Pletcher, Mark
PUB. DATE
November 2013
SOURCE
JGIM: Journal of General Internal Medicine;Nov2013, Vol. 28 Issue 11, p1483
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: Recent data suggest that aspirin may be effective for reducing cancer mortality. OBJECTIVE: To examine whether including a cancer mortality-reducing effect influences which men would benefit from aspirin for primary prevention. DESIGN: We modified our existing Markov model that examines the effects of aspirin among middle-aged men with no previous history of cardiovascular disease or diabetes. For our base case scenario of 45-year-old men, we examined costs and life-years for men taking aspirin for 10 years compared with men who were not taking aspirin over those 10 years; after 10 years, we equalized treatment and followed the cohort until death. We compared our results depending on whether or not we included a 22 % relative reduction in cancer mortality, based on a recent meta-analysis. We discounted costs and benefits at 3 % and employed a third party payer perspective. MAIN MEASURE: Cost per quality-adjusted life year (QALY) gained. KEY RESULTS: When no effect on cancer mortality was included, aspirin had a cost per QALY gained of $22,492 at 5 % 10-year coronary heart disease (CHD) risk; at 2.5 % risk or below, no treatment was favored. When we included a reduction in cancer mortality, aspirin became cost-effective for men at 2.5 % risk as well (cost per QALY, $43,342). Results were somewhat sensitive to utility of taking aspirin daily; risk of death after myocardial infarction; and effects of aspirin on stroke, myocardial infarction, and sudden death. However, aspirin remained cost-saving or cost-effective (< $50,000 per QALY) in probabilistic analyses (59 % with no cancer effect included; 96 % with cancer effect) for men at 5 % risk. CONCLUSIONS: Including an effect of aspirin on cancer mortality influences the threshold for prescribing aspirin for primary prevention in men. If such an effect is real, many middle-aged men at low cardiovascular risk would become candidates for regular aspirin use.
ACCESSION #
91096900

 

Related Articles

  • Low-dose aspirin cost saving in CVD.  // PharmacoEconomics & Outcomes News;7/11/2009, Issue 582, p4 

    The article focuses on a study presented at the 69th Annual Scientific Sessions of the American Diabetes Association which showed that low-dose aspirin in patients with or without diabetes mellitus is cost saving for patients at a 4% cardiovascular disease (CVD) risk or higher in the U.S. The...

  • Cardio-oncology: A new focus for cardiovascular medicine. Hundley, W. Gregory // Hem/Onc Today;8/10/2011, Vol. 12 Issue 15, p20 

    The author reflects on the increased incidence of premature cardiovascular (CV) events in populations of cancer survivors in the U.S. as advances in treatment have reduced cancer-related mortality.

  • The relationship between depression and medical illness. Katon, Wayne J.; Wulsin, Lawson R.; Spiegel, David; Pinkowish, Mary; Georgi, Kristen // Patient Care;Oct2005, Vol. 39 Issue 10, p12 

    Discusses the coexistence of depression with medical illnesses. Rate of the occurrence of depression in diabetes patients according to National Institutes of Health; Results of a study on the relationship between depression and the risk of cardiovascular disease; Factors to consider in reading...

  • Health disparities: A barrier to high-quality care. Mullins, C. Daniel; Blatt, Lisa; Gbarayor, Confidence M.; Hui-Wen Keri Yang; Baquet, Claudia // American Journal of Health-System Pharmacy;9/15/2005, Vol. 62 Issue 18, p1873 

    Purpose. Disparities in the treatment of cardiovascular disease, diabetes mellitus, and cancer among the sexes and racial groups and possible interventions are discussed. Summary. The ongoing process to identify and reduce health disparities has engaged numerous federal agencies as they monitor...

  • Picotamide likely cost effective vs aspirin for preventing CV events.  // PharmacoEconomics & Outcomes News;1/27/2007, Issue 520, p8 

    The article reports on the cost effectiveness of picotamide in preventing cardiovascular events among patient with diabetes and peripheral arterial disease. According to study conducted by researchers from Italy, they created a Markov model to determine the cost effectiveness of lifetime...

  • Aspirin use differs with men and women with diabetes.  // Patient Care;Jan2005, Vol. 39 Issue 1, p6 

    Discusses research being done to determine the extent of self-reported aspirin use among patients with diabetes. Reference to a study by S. D. Persell and D. W. Baker published in a 2004 issue of "Archives of Internal Medicine"; Percentage of aspirin use among diabetic adults with...

  • Male childhood cancer survivors had greater adiposity, cardiovascular risk factors. Brannon, Matthew; Fisher, Stacey L.; Foster, Melissa; Moskowitz, Andrew // Infectious Diseases in Children;Oct2010, Vol. 23 Issue 10, p53 

    The article presents a research that found greater adiposity and cardiovascular risk factors in male childhood cancer survivors than female cancer survivors and healthy siblings.

  • Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease. Picozzi, Stefano; Marenghi, Carlo; Ricci, Cristian; Bozzini, Giorgio; Casellato, Stefano; Carmignani, Luca // Surgical Endoscopy;Jan2014, Vol. 28 Issue 1, p116 

    Background: Urologists have not reached a consensus regarding the pre-, intra-, and postoperative management of patients taking antiplatelet agents. This study aimed to evaluate the clinical course of patients receiving antithrombotic monotherapy with acetylsalicylic acid (ASA) 100 mg who...

  • BMD test/alendronate combo cost effective for PCa patients on ADT.  // Urology Times;Jul2010, Vol. 38 Issue 8, p50 

    The article discusses the cost effectiveness of bone mineral density mixed with alendronate for prostate cancer patients who undergoes androgen deprivation therapy.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics